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Abstract Is bariatric surgery as primary therapy for
type 2 diabetes mellitus (T2DM) with body mass index
(BMI) <35 kg/m2 justified? Open-label studies have shown
that bariatric surgery causes remission of diabetes in some
patients with BMI <35 kg/m2. All such patients treated had
substantial weight loss. Diabetes remission was less likely in
patients with lower BMI than those with higher BMI, in
patients with longer than shorter duration and in patients with
lesser than greater insulin reserve. Relapse of diabetes in-
creases with time after surgery and weight regain. Deficien-
cies of data are lack of randomized long-term studies
comparing risk/benefit of bariatric surgery to contemporary
intensive medical therapy. Current data do not justify bariatric
surgery as primary therapy for T2DM with BMI <35 kg/m2.
Keywords Metabolic surgery . Type 2 diabetes . Bodymass
Index <35 kg/m2 . Remission of diabetes
Introduction
The worldwide epidemic of type 2 diabetes is increasing at a
rate far exceeding previous predictions. It is now projected
that the number of persons with diabetes in 2030 will be 552
million [1]. Since diabetes is the cause of 40–55 % of end-
stage renal disease, 50–60 % of coronary artery disease, a
preponderance of visual loss in adults and the majority of
non-traumatic lower extremity amputations, its impact on
population health and health care costs are and will be
increasingly enormous [2]. It is within this context that we
are struggling to develop strategies to prevent diabetes and
treatments to reduce its chronic complications.
The great increase in type 2 diabetes has been due to
environmental changes, many of which have resulted in
obesity associated with the metabolic syndrome and all of
its consequences. The prevention and/or the treatment of
obesity results in decreases in the development of type 2
diabetes and, where diabetes already exists, marked im-
provements in its metabolic abnormalities [3–5]. Unfortu-
nately, lifestyle modification with or without pharmacologic
therapy has been relatively ineffective as a therapeutic en-
deavor to treat obesity.
A consequence of the ineffective medical therapy for
obesity has been the development of a number of surgical
procedures to cause and maintain weight loss [6, 7]. These
procedures have been termed bariatric surgery and have
been quite effective in reducing morbidity and mortality in
individuals with severe obesity [8–12]. As approximately
20 % of individuals with severe obesity have concomitant
type 2 diabetes, it has been possible to show that bariatric
surgery results in marked improvement of diabetes [10, 12].
More recently, many studies have indicated that bar-
iatric surgery in patients with type 2 diabetes and type 2
(body mass index [BMI] 35 to <40 kg/m2) or type 3
obesity (BMI ≥40 kg/m2) causes remission or improvement of
the diabetes [7, 8, 10, 12]. As a result of these findings, the
obvious question to be asked is whether bariatric surgery
should be considered as a primary treatment for diabetes in
overweight and type 1 obese individuals with type 2 diabetes.
Evidence for and against the use of bariatric surgical pro-
cedures to treat the ordinary individual with type 2 diabetes
is the subject of this analysis.
The Role of Obesity in Generating Metabolic
Abnormalities of Type 2 Diabetes
Before we can address the role that obesity plays in the
pathogenesis of the metabolic abnormalities of type 2
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diabetes, we need to have a definition of obesity. The current
classification of obesity is based on the BMI, which is
defined as weight in kilograms divided by height in meters
squared [13]. A BMI from 25.0 to 29.99 is defined as
overweight and a BMI greater than 30.0 is defined as obese
[13]. Obesity is further subdivided into type I (BMI 30.0 to
34.99 kg/m2), type II (BMI 35.0 to 39.99 kg/m2) and type III
(BMI greater than 40.0 kg/m2)[13]. These criteria, however,
fail to take into consideration the percentage of body fat or
distribution of body fat and therefore are only moderately
correlated with true body fatness.
The metabolic abnormalities associated with an in-
crease in body fat (metabolic syndrome and insulin
resistance syndrome) are correlated most strongly with
hepatic triglyceride content and visceral adiposity mass
rather than subcutaneous adiposity or total body fat [14,
15]. It is the insulin resistance and its associated abnor-
malities (dyslipidemia, increased blood pressure, endo-
thelial dysfunction and pro-coagulant state) that drive
the development and progression of type 2 diabetes in
individuals with genetically predisposed beta cell abnor-
malities [16]. In a study of 538 obese individuals with
fasting plasma glucose (FPG) ≤120 mg/dl and
BP <160/90 mm of Hg, euglycemic hyperinsulinemic
clamps showed that insulin resistance was present in
only 34 % of individuals with BMI <35 kg/m2, but in
60 % of those with BMI >35 kg/m2 [17].
Overweight and obese individuals therefore can be divid-
ed into those with and without metabolic disorders. The
prevalence of the metabolic syndrome in individuals with
type 2 diabetes is approximately 80 %.
Mechanisms by Which Bariatric Surgery Improves
Hyperglycemic and Cardiovascular risk Factors
in Patients with the Metabolic Syndrome
and Type 2 Diabetes
The current clinically accepted bariatric surgical procedures
are laparoscopic gastric banding (LGB), Roux-en-Y gastric
bypass (RYGB), sleeve gastrectomy and bilio-pancreatic
diversion with a duodenal switch (BPD/DS). The mechanisms
by which these procedures exert their effects are food restric-
tion, malabsorption and alterations in upper and lower gastro-
intestinal hormonal and metabolic factors [7, 18–20]. Gastric
banding is a restrictive procedure and decreases hyper-
glycemia proportional to the magnitude and time course
of weight loss [18]. Sleeve gastrectomy appears to have
both restrictive effects through food restriction and
weight loss and additionally alterations in lower gastro-
intestinal hormone and metabolic factors. RYGB which
is primarily a diversionary procedure improves hypergly-
cemia within several weeks of the surgery and before
significant weight loss has occurred suggesting that non-
weight loss factors, such as alterations in upper and
lower gastrointestinal metabolic factors, are responsible
for a significant component of the observed clinical
benefits [7, 18–20]. BPD/DS benefits are due to a com-
bination of diversionary effects plus a significant malab-
sorption component [7].
A major issue in assessing the mechanisms responsible
for the improvements in diabetes in diversionary surgical
procedures is the difficulty in quantifying the effects of food
restriction itself from the other non-weight loss components
of the various bariatric surgical procedures. Short-term ex-
periments in patients with type 2 diabetes have demonstrat-
ed that caloric restriction, independent of weight loss,
improves glycemic control [21]. A recent study in obese
patients with type 2 diabetes put on a 600-kcal diet for
8 weeks showed rapid improvement in FPG and HbA1c,
which were observed after 1 week (Table 1) despite the
small changes in body weight and BMI [22]. The most
dramatic changes after 1 week of caloric restriction were
the decrease in liver triglycerides and in fat mass (Table 1)
[22]. After 8 weeks, FPG and HbA1C were normalized [22].
Body weight and BMI were decreased 14.8 % and 14.6 %,
respectively, but again the most dramatic effects of the
caloric restriction were a 77 % decrease in hepatic triglyc-
erides and a 33 % decrease in body fat (Table 1) [22].
It is apparent that caloric restriction after complex surgi-
cal procedures can account for at least part of the early
benefits in improving hyperglycemia in patients with type
2 diabetes. The role of changes in ghrelin, GLP-1 and PYY
secretion following diversionary surgical procedures need to
Table 1 Metabolic effects of an
8-week 600 kcal/day in 11 pa-
tients with type 2 diabetes
Baseline characteristics: weight
103.7±4.5 kg, BMI 33.6±
1.2 kg/m2, fat mass 39.0±3.5 kg,
hepatic triglyceride 12.8 %. Data
are from Lim et al. [22]
Parameter Baseline Week 1 Week 4 Week 8
Weight (% baseline) 100 96.1 90.7 85.2
BMI (% baseline) 100 96.1 90.8 85.4
Fat Mass (% baseline) 100 93.8 81.3 67.4
Hepatic Triglyceride (% baseline) 100 70 23
Fasting plasma glucose (mmol/l) 9.2 5.9 5.7 5.7
HbA1C (%) 7.4 7.1 6.5 6.0
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be defined by physiologic experiments rather than just by
plasma measurements.
Is BMI the Best Parameter for Selection of Patients
for Metabolic Surgery for the Treatment of Type 2
Diabetes?
The metabolic abnormalities of type 2 diabetes are amelio-
rated either by an increase in insulin availability or a de-
crease in insulin resistance. Weight loss in obese individuals
with insulin resistance will improve insulin sensitivity and
in those with diabetes improves hyperglycemia [4, 22].
Improving hyperglycemia decreases glucose toxicity, which
improves insulin secretory function. Insulin resistance in
overweight and obese individuals is caused by the disposi-
tion of excess quantities of lipids, lipid metabolites and
adipokines into non-adipose tissue cells such as muscle,
liver and endothelial cells [23]. These excess lipid deposits
block the intracellular action of insulin and result in insulin
resistance [23]. Recent studies indicate that insulin resis-
tance is secondary to an increase in hepatic triglyceride
content as well as an increase in visceral adiposity [14, 15,
23]. Decreasing hepatic steatosis and reducing visceral ad-
ipose tissue mass decreases insulin resistance. While BMI
partially reflects adipose tissue mass, it is also determined
by non-adipose tissue factors and is not a good measure of
either hepatic triglyceride content or visceral adipose tissue
mass. BMI therefore, while an easily obtainable and cheap
measurement is nonetheless a poor index of metabolically
significant obesity [24].
The use of BMI to determine the potential benefits of
metabolic surgery for resolution or improvement in diabetes
management therefore should not be considered a stringent
criterion as it is not a measure of metabolically significant
abnormalities associated with obesity [14, 15, 24].
How Important Is Weight Loss in the Resolution
of Diabetes by Bariatric Surgery in Individuals
with BMI <35 kg/m2?
Relatively few studies have examined the effects of bariatric
surgery in patients with type 2 diabetes and BMI <35 kg/m2
[25]. Table 2 lists data from four recent studies. Lee and
colleagues [26] examined the data from their large series of
laparoscopic mini-gastric bypass surgery reported the results
of those with baseline BMI <35 kg/m2 and those with
BMI >35 kg/m2. The percent weight loss was almost as great
in those with baseline BMI <35 kg/m2 as it was in those with
>35 kg/m2. Cohen and colleague’s [27] patients with baseline
BMI <35 kg/m2 lost 35–40 % of their body weight in 1 year
[27]. Similarly, Schauer et al. [28] though not giving specific
details for their patients with BMI <35 kg/m2 reported weight
losses of approximately 25 % in their surgically treated pa-
tients. Lee et al. [29] in a multicenter study of 200 patients
with diabetes and BMI <35 kg/m2 reported on a 1-year
follow-up of 87 patients, most of whom had gastric bypass
surgery, that the mean body weight loss was 19.4 %.
It is therefore difficult to make a major distinction be-
tween the effects of gastric bypass surgery and sleeve gas-
trectomy on the magnitude of body weight reduction
between patients with type 2 diabetes with BMI <35 and
>35 kg/m2 as both groups have a striking decrease in body
weight. The magnitude of weight loss has to be a major
factor in the improvement of metabolic abnormalities in
obese patients with type 2 diabetes irrespective of whether
their baseline BMI is <35 or >35 kg/m2. However, the
magnitude of improvement in diabetes does appear to be
less in those with the lower BMI as compared to those with
the higher BMI. The same appears to be true with the
recurrence rate of diabetes after remission, being higher in
the lower baseline BMI population than in the higher base-
line BMI population.
Table 2 Weight loss following gastric bypass surgery in patients with BMI <35 kg/m2 and 1 year follow-up
Author Number of patients





Weight loss 1 year Weight loss 5 years
(kg) % body wt
Lee et al. [26] 44 (21.9 %) 31.7 24 30 % Approximately 36 %
Schauer et al. [28]
Gastric bypass 14 (28 %) 37.0 106.7 29.4 27.6 %
Sleeve gastrectomy 18 (36 %) 36.1 100.8 25.1 24.5 %
Cohen et al. [27] 66 32.7 36 %
40 %
Lee et al. [29] 87 28.5 19.4 %
Gastric bypass 86 % 20.3
Restrictive procedure 14 % 15.4
802 OBES SURG (2013) 23:800–808
Results of Bariatric Surgery in Patients with Type 2
Diabetes: BMI <35 kg/m2 as Compared to >35 kg/m2
The glycemic benefits of metabolic surgery in patients with
type 2 diabetes and BMI <35 kg/m2 have been reported in
several recent publications. The results of early postopera-
tive outcomes from the ASMBS Bariatric Surgery Center of
Excellence Program have been reported on 235 patients
operated upon from July 2007 to June 2009 with BMI ≥30
but <35 kg/m2 with diabetes requiring treatment with med-
ications [30]. Comparisons were carried out between 109
who had adjustable gastric banding and 109 patients who
had gastric bypass surgery. Laparoscopic access was used in
92 % of the patients. The diabetes pre-operatively had been
treated with oral agents alone (gastric bypass 53.3 %; ad-
justable gastric banding 66.1 %), or insulin alone or with
oral agents (gastric bypass 43.1 %; adjustable gastric
banding 33.1 %). Follow-up data were available for
6–12 months in a little more than 50 % of the patients.
The BMI decreased from 33.1 to 27.2 (14.5 %) at 6 months
in the gastric bypass group and from 33.9 to 31.0 (8.6 %) in
the adjustable gastric banding group. Percent excess body
weight decreased from 57 % to 26.8 % after gastric bypass
and 45.5 % after adjustable gastric banding. The effect on
diabetes was not measured by changes in HbA1C or FPG
but rather by the change in diabetic treatments. After 6 to
12 months, 50 % of gastric bypass and 31.8 % of adjustable
gastric band patients were no longer taking diabetes medi-
cations. Among patients initially taking insulin plus oral
medications, 11.1 % and 50 % had no need for diabetes
medications 6 months after adjustable gastric banding and
gastric bypass, respectively. The number of significant post-
operative complications through 90 days reached 20 follow-
ing gastric bypass and three following adjustable gastric
banding.
Shimizu et al. [31] have reviewed and summarized 18
published studies involving 477 patients with type 2 diabe-
tes and BMI <35 kg/m2 that were treated surgically for type
2 diabetes. Of the 18 studies, seven were done in Brazil, four
in Italy, four in Taiwan, one in Chile, one in the US and one
in India. Surgical procedures included RYGB in six, duode-
nal–jejunal bypass in four, biliopancreatic diversion (BPD)
in three, mini gastric bypass in two, ileal interposition with
sleeve or diverted sleeve gastrectomy in two, sleeve gastrec-
tomy in one and stomach and pylorus-preserving BPD in 1.
Thirty percent of the patients had been treated with insulin
prior to the surgical procedure. The follow-up period ranged
from 6 to 216 months. The mean changes in BMI, FPG and
HbA1C for the studies in which they were reported are
shown in Fig. 1. Note that the mean BMI decreased from
30.4±0.98 to 24.8±0.33 kg/m2. Remission of diabetes as
defined by FPG <126 mg/dl and HbA1C <6.5 % without the
use of antidiabetic medications [32] was reported in 64.7 %
of patients. When patients were stratified by duration of
diabetes at the time of surgery, insulin use was 18.2 % in
those with diabetes duration ≤8 years and 45.9 % in those
>8 years and the remission rates after surgery were 66 % in
those with the shorter duration and 52.9 % in those with the
longer duration of diabetes. Postoperative complications oc-
curred in 10.3 % of the patients with no reported mortalities.
The risk of excessive weight loss after surgery was 2.7 %.
Lee and colleagues have reported the results of a multi-
institutional study of metabolic surgery in 200 Asian pa-
tients with type 2 diabetes and BMI <35 kg/m2. One hun-
dred seventy two patients had a gastric bypass, 24 sleeve
gastrectomy, and four adjustable gastric banding. Mean
baseline HbA1C was 9.3±1.9 % and the end point, which
was remission of diabetes, was defined as FPG <110 mg/dl
and HbA1C <6.0 % in the absence of any diabetic medica-
tions. One-year data were available for 87 patients [29].
BMI decreased from 28.5±3.0 to 23.4±2.3 kg/m2, body
weight loss was 19.4 %, and HbA1C decreased to 6.3±0.
5 %. Remission of diabetes was achieved in 72.4 % of the
patients. The remission rate was higher in those with diabetes
duration <5 years (90.3 %) compared to those with duration
>5 years (57.1 %); those with BMI >30 kg/m2 (78.7 %) than
those <30 kg/m2 (62.5 %) and in those following gastric
bypass than in those following restrictive-type procedures
(Fig. 2). Following metabolic surgery, the patients had sig-
nificant improvement in waist circumference, systolic and
diastolic blood pressure, total and LDL-cholesterol, triglyc-
erides and HOMA-IR.
The longest and most complete follow-up on patients
with type 2 diabetes with BMI <35 kg/m2 who have been
treated by metabolic surgery was recently published by
Cohen and associates [27]. They did a gastric bypass in 66












Fig. 1 The results of metabolic surgery in patients with type 2 diabetes
and BMI <35 kg/m2. The data are the result of meta-analyses from 14
studies for the change in BMI, 12 studies for the change in fasting
plasma glucose (FPG) and ten studies for the change in HbA1C. Data
are derived from Shimizu et al. [31]
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diabetes poorly controlled on medical therapy (mean
HbA1C 9.7±1.1.5 %). The follow-up rate which extended
up to 6 years was 100 %. Durable diabetes remission
(HbA1C <6.5 % without diabetes medications) has occurred
in 88 % of the patients with improvement in glycemia in an
additional 11 %. The mean HbA1C after surgery was 5.9±0.
1 %. The majority of patients discontinued diabetes medi-
cations. The initial mean BMI was 32.7 kg/m2. The mean
weight loss at last follow-up was 37 % in those whose
diabetes improved and 40 % of those whose diabetes went
into remission. Mean waist circumference decreased from
123 to 88 cm in those with type 2 diabetes resolved and
85 cm in those with diabetes improved. Associated meta-
bolic improvements following surgery were noted in
systolic and diastolic blood pressure, total, LDL and HDL
cholesterol and triglycerides.
The data indicate that gastric bypass surgery is effec-
tive as a treatment for type 2 diabetes with BMI 30 to
34.9 kg/m2. The data which are available suggest that
the benefits in diabetes resolution and improvement are
not as great in those with BMI <35 as in those with
BMI >35 kg/m2. In all BMI categories, shorter duration
of diabetes, less severe baseline hyperglycemia and oral
agent therapy are predictors of better resolution of dia-
betes following metabolic surgery.
Recurrence of Diabetes After Metabolic Surgery
Induced Remission
Long-term follow-up of patients with type 2 diabetes who
have had diabetes remission or significant improvement
show that there is a recurrence rate that increases with length
of time after the surgery (Table 3). In the Swedish Obesity
Study (SOS), the remission rate for diabetes after bariatric
surgery was 72 % after 2 years compared to a control
population where it was 21 %. However, after 10 and
15 years of follow-up, the diabetes remission rate had
fallen to 36 % and 30 %, respectively, for the surgically
treated group and was 13 % and 6 %, respectively, for the
control group [8]. The diabetic population in the SOS
study had a mean initial BMI 42.1 kg/m2. Diabetes re-
mission following surgery correlated with a shorter dura-
tion of diagnosed diabetes at baseline and a larger weight
loss at 2 years. Relapse of diabetes remission was associ-
ated with longer diabetes duration at baseline, higher
baseline body weight, higher baseline plasma glucose,
smaller weight loss at 2 years and a smaller reduction of


















Fig. 2 The relationship between baseline BMI and baseline duration
of known diabetes with the percent of patients with remission of their
diabetes 1 year after metabolic surgery. The data are derived from 87
of 200 patients who had achieved a 1-year follow-up in a multi-
institutional international Asian study. Data are derived from Lee
et al. [29]
Table 3 Re-emergence of diabetes after resolution with bariatric surgery during long-term follow-up








Sjostrom et al. [8] Vertical banded 345 229 (72 %) 0 % 2 years
gastroplasty (71 %) 50 % 10 years
Gastric banding (24 %) 58.3 % 15 years
Gastric bypass (5 %)
Kim and Richards [36] Gastric bypass 219 156 (71 %) 11 (7.1 %) 2 to 5 years
DiGiorgi et al. [34] Roux-en-Y-gastric bypass 42 27 (64 %) 10 (24 %) ≥3 years
Chikunguwo et al. [33] Roux-en-Y gastric bypass 177 157 (89 %) 68 (43 %) Within 5 years
Ramos et al. [35] Not specified 72 66 (91.6 %) 14 (21.2 %) 5<2 years
3 at year 3
3 at year 4
3 at year 5
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In Chikunguwo et al.'s series, durable remissions were
most likely to occur in men, early in the time course of
diabetes and in those controlling their diabetes with diet
and/or oral hypoglycemic agents [33]. DiGiorgi and associ-
ates [34] noted that lower preoperative BMI, a greater
weight loss failure rate, regain of a greater percentage of
the lost weight, and a higher postoperative glucose level
predicted recurrence of the diabetes. Patients who required
insulin or oral medications before metabolic surgery were
more likely to have improvement in their diabetes rather
than remission of their diabetes. In Ramos et al.’s study [35],
preoperative diabetes duration predicted late recurrence. In
the subset of patients with diabetes duration of 5 years or
longer, the odds ratio for recurrence was 3.8.
The recurrence data [8, 33–36] can be summarized as
showing that long duration of diabetes, more severe hyper-
glycemia and more intense medical treatment preoperatively
predict a higher rate of long term recurrence of diabetes in
those who initially have a remission of their diabetes. These
data suggest that bariatric surgery slows but does not pre-
vent the progressive deterioration of beta bell function in
patients with type 2 diabetes.
Surgical and Metabolic Complications Following
Metabolic Surgery
Equally as important as the remission and improvement rate
of diabetes following bariatric surgery are the rates and
severity of complications from the surgical procedures and
the long term outcomes of these procedures. Relatively little
data are available on the short and long-term complications
of bariatric surgical procedures because of the paucity of
long-term follow-up studies and the inordinately large drop-
out rates of most of the studies that are reported. While the
long-term outcome data of bariatric surgery in the severely
obese is inadequate, it is virtually non-existent in individuals
with type 2 diabetes with BMI <35 kg/m2.
A recent review of early outcomes of bariatric surgery
from the Bariatric Outcomes Longitudinal Database [37]
compared the results in patients with the metabolic syn-
drome (23,106) to those without the metabolic syndrome
(163,470). Gastric bypass had been done in 62 % of the
patients and gastric banding in 32 %. Mean baseline BMI
was 46.9 kg/m2. Compared to patients without the metabolic
syndrome, patients with the metabolic syndrome had an
increase in serious complications (2.4 to 1.0 %),
readmissions to the hospital (6.2 to 4.7 %) and mortality
(0.3 to 0.1 %) within 90 days of operation. The 12 months
remission rate for diabetes in the metabolic syndrome pa-
tients who had had gastric bypass surgery was 62 %
A study comparing complications of gastric bypass to
gastric banding with a 92.3 % follow-up at 6 years in 442
patients matched for sex, age and BMI showed that RYGB
had a higher early (17.2 % vs. 5.4 %) but lower late com-
plication rate than gastric banding (LB) [38]. Total compli-
cations following RYGB occurred in 42 patients (19 %) and
included anastomotic strictures, marginal ulcers, small bow-
el obstruction secondary to adhesions or internal hernias and
symptomatic small bowel or incisional hernias [38]. Re-
operation was necessary in 12.7 % of patients. In the gastric
band patients, total complications were 92 (41.6 %) and
included port/catheter leak, band leak, port or band infec-
tion, band erosion, pouch or esophageal dilatation, gastric
esophageal reflux, and food intolerance [38]. Re-operation
was necessary in 26.7 % of the patients and band removal
was necessary in 47 (21.3 %) of the patients. RYGB had a
greater 6-year weight loss and success rate than gastric
banding. Other studies have shown similar complication
rates for the two procedures in severely obese patients
[39–43].
Table 4 lists the complications of gastric bypass surgery
in three recently published series with somewhat lower
mean BMI and a 1-year follow-up [26, 28, 44]. The results
parallel those of earlier studies with more severely obese
individuals.
Another aspect to the short- and long-term complications
of bariatric surgery are the nutritional disturbances which
can and frequently are the consequences of alterations in
gastrointestinal physiology which occur after the various
surgical procedures. These have been reviewed extensively
in other publications [45–49]. They can lead to acute syn-
dromes such as Wernicke’s syndrome and protein malnutri-
tion, and more chronic problems such as iron deficiency
with anemia, vitamin D and calcium deficiency with bone
disease, vitamin B12 and folate deficiencies, vitamin A
deficiency, as well zinc, magnesium selenium, and copper
deficiencies.
Conclusions
After having evaluated the available evidence, what conclu-
sions can we reach concerning the role of metabolic surgery
as a primary treatment for patients with BMI <35 kg/m2 and
type 2 diabetes. Bariatric surgery resolves or improves hy-
perglycemia and the metabolic syndrome in a majority of
type 2 diabetic patients with BMI 30 to 35 kg/m2. The
beneficial effects on diabetes are most likely to occur in
those with diabetes duration <5 years who still have signif-
icant beta cell functional reserve as demonstrated by some
responsiveness to dietary and oral agent therapies. The
lower the BMI in the type I obesity and overweight range,
the less responsive the diabetes will be to bariatric surgery.
Though non-weight loss factors play a role in the improve-
ment seen in the diabetes in patients with BMI <35 kg/m2,
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all studies with the traditional bariatric surgery procedures
have shown remarkable weight loss — frequently restoring
the BMIs of patients to within the normal weight range.
Since significant weight loss by medical and/or dietary
therapy in this population can achieve the same short-term
results as bariatric surgery [21, 22, 50], it might be reason-
able to speculate that the major difference between bariatric
surgery and dietary management is the lack of sustainable
effect in dietarymanagement versus the sustainability of weight
loss by gastric bypass or other bariatric surgical procedures.
Evidence that bariatric surgery does not stop — but
rather, slows down — the progression of the beta cell
decline in patients with type 2 diabetes are the data that
bariatric surgery induced remission of diabetes lessens with
time and that relapses of the diabetes are being reported with
increasing frequency as more long-term follow-up data are
being reported (Table 3).
The biggest drawback to recommending bariatric
(metabolic) surgery for treating patients with diabetes and
BMI <35 kg/m2 are the lack of randomized, controlled
clinical trials comparing contemporary intensive lifestyle
and pharmacologic treatment to bariatric surgical treatment.
Several recent papers have discussed the issues of medical
therapy for patients with type 2 diabetes [51, 52]. Large
clinical trials have been able to maintain HbA1C at 6.5–
6.9 % for periods as long as 3 to 7 years. With newer
agents for weight loss and glycemic control about to
enter the market place, metabolic and weight control
should improve. Additionally, several very important clin-
ically meaningful questions need to be answered as we
evaluate the benefits of medical versus metabolic surgery
treatments. Are HbA1C levels <6.5 % necessary to re-
duce diabetic complications or is <7 % adequate? How
much weight loss in patients with BMI 30 to 35 kg/m2 is
necessary to achieve the metabolic benefits of weight
loss? Could it be as little as 5–10 % of body weight?
An even more vexing question is whether the benefits of
bariatric surgery in patients with type 2 diabetes and BMI
27–35 kg/m2 are sufficient to justify the side effects of the
procedures [51, 53]. An operative mortality of 0.2–0.3 %
means that for every 1,000 patients with type 2 diabetes and
BMI <35 kg/m2, there will be two to three deaths. This is
unacceptable for a disease that can be effectively treated
medically. As shown in Table 4, even in the best surgical
Table 4 Reported short-term
(1 year) complications in several
recently published clinical trials
of bariatric surgery in patients
with type 2 diabetes
Complication Gastric bypass
DeMaria et al. 90
days after operation
109 patients [30]
Schauer et al. 1
year 50 patients [28]








Hemoglobin decrease >5 g/dl 1
Cholelithiasis 1
Common bile duct obstruction 1
Gastrointestinal bleeding 1
Hypokalemia 2
Internal hernia 1 1
Intestinal obstruction 1
Intravenous treatment for dehydration 4
Ketoacidosis 1






Surgical wound infection 1 1
Transient renal insufficiency 1
Transfusion 1
Vitamin K deficiency 1
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centers, complications following RYGB surgery are very
frequent and significant. If randomized, controlled studies
of bariatric surgery versus the best contemporary medical
management show that long-term clinical outcomes are
better and that the benefit/risk ratio is greater with bariatric
surgery than the best contemporary medical treatments, we
will have a strong argument for metabolic surgery as a
primary therapy for ordinary type 2 diabetes.
Until we have such data, which will take many years to
obtain, what should be our current position regarding met-
abolic surgery as a treatment for type 2 diabetes in patients
with BMI <35 kg/m2? Since diabetes regulation and cardio-
vascular risk factor reductions respond well to bariatric
surgery in patients with type 2 diabetes with BMI ≥27 and
<35 kg/m2, it should be considered as an option in those
patients that cannot be adequately controlled on intensive
medical therapy. The more obese the type 2 diabetic patient
is, the more likely the potential benefit that can be obtained
with metabolic surgery. The less overweight the patient, the
less likely that there will be a meaningful benefit. In any
event, a thorough discussion with the patient about the risks
as well as the potential benefits needs to be discussed.
Metabolic surgery is not a benign procedure and should
only be undertaken if adequate intensive medical therapy
is failing.
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